Abstract
Glioblastoma is the most aggressive adult primary brain tumor. Although progress has been made in understanding the molecular mechanisms underlying these tumors, current treatments are ineffective. Recent studies have identified iNOS as a critical regulator of glial transformation downstream of EGFRvIII/STAT3 signaling, a key oncogenic pathway in glioblastoma. STAT3 directly binds the promoter of the iNOS gene and thereby stimulates its expression. Importantly, inhibition of iNOS by genetic and pharmacological approaches impedes glial cell proliferation, invasiveness, and tumor growth in vivo. iNOS expression is also elevated in a population of human brain tumor stem cells (BTSCs), and iNOS is required for BTSC proliferation and tumorigenesis. Together, these findings suggest that development of iNOS-targeted therapies may prove valuable in the treatment of glioblastoma. Here, we review our current understanding of iNOS signaling in the regulation of glioblastoma pathogenesis and the potential mechanisms by which iNOS inhibition might suppress the malignant behavior of these devastating tumors.
Keywords: Astrocytes, brain tumor stem cells, EGFRvIII, glioblastoma, invasiveness, iNOS, NO, proliferation, STAT3, signaling.
Current Molecular Medicine
Title:iNOS: A Potential Therapeutic Target for Malignant Glioma
Volume: 13 Issue: 8
Author(s): A. Jahani-Asl and A. Bonni
Affiliation:
Keywords: Astrocytes, brain tumor stem cells, EGFRvIII, glioblastoma, invasiveness, iNOS, NO, proliferation, STAT3, signaling.
Abstract: Glioblastoma is the most aggressive adult primary brain tumor. Although progress has been made in understanding the molecular mechanisms underlying these tumors, current treatments are ineffective. Recent studies have identified iNOS as a critical regulator of glial transformation downstream of EGFRvIII/STAT3 signaling, a key oncogenic pathway in glioblastoma. STAT3 directly binds the promoter of the iNOS gene and thereby stimulates its expression. Importantly, inhibition of iNOS by genetic and pharmacological approaches impedes glial cell proliferation, invasiveness, and tumor growth in vivo. iNOS expression is also elevated in a population of human brain tumor stem cells (BTSCs), and iNOS is required for BTSC proliferation and tumorigenesis. Together, these findings suggest that development of iNOS-targeted therapies may prove valuable in the treatment of glioblastoma. Here, we review our current understanding of iNOS signaling in the regulation of glioblastoma pathogenesis and the potential mechanisms by which iNOS inhibition might suppress the malignant behavior of these devastating tumors.
Export Options
About this article
Cite this article as:
Jahani-Asl A. and Bonni A., iNOS: A Potential Therapeutic Target for Malignant Glioma, Current Molecular Medicine 2013; 13 (8) . https://dx.doi.org/10.2174/1566524011313080002
DOI https://dx.doi.org/10.2174/1566524011313080002 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Brain Cancer-Activated Microglia: A Potential Role for Sphingolipids
Current Medicinal Chemistry Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and Treatment
Current Gene Therapy Emerging Therapies in the Treatment of Locally Advanced Squamous Cell Cancers of Head and Neck
Recent Patents on Anti-Cancer Drug Discovery Existing Drug Repurposing for Glioblastoma to Discover Candidate Drugs as a New a Approach
Letters in Drug Design & Discovery Proteomics Approach to Illustrate Drug Action Mechanisms
Current Drug Discovery Technologies A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Editorial [Hot Topic: Immunotherapy of Cancer (Guest Editors: Ezra E.W. Cohen and Nikolai G. Rainov)]
Reviews on Recent Clinical Trials Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Metastasis-Inducing S100A4 Protein: Implication in Non-Malignant Human Pathologies
Current Molecular Medicine Targeting 5-Lipoxygenase for Prevention and Treatment of Cancer
Current Enzyme Inhibition New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design Patent Selections
Recent Patents on DNA & Gene Sequences Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology Non-Photoinduced Biological Properties of Verteporfin
Current Medicinal Chemistry Anthraquinones: Analytical Techniques as a Novel Tool to Investigate on the Triggering of Biological Targets
Current Drug Targets miR-629-3p Level Significantly Predicts Prognosis in Glioblastoma Patients Treated with Temozolomide Chemotherapy
Current Signal Transduction Therapy Gold Nanostructures as Photothermal Therapy Agent for Cancer
Anti-Cancer Agents in Medicinal Chemistry Is Ecto-nucleoside Triphosphate Diphosphohydrolase (NTPDase)-based Therapy of Central Nervous System Disorders Possible?
Mini-Reviews in Medicinal Chemistry